Joseph Puente, MD
Family Medicine · Sinton, TXNPI 1356312730
Payments from drug & device makers
Across 282 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$889
- Sanofi-aventis U.S. LLC$725
- Lilly USA, LLC$712
- Astellas Pharma US Inc$515
- AstraZeneca$418
- Novartis$301
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,58495%
- Education$2625%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $889 |
| Sanofi-aventis U.S. LLC | 47 | $725 |
| Lilly USA, LLC | 48 | $712 |
| Astellas Pharma US Inc | 22 | $515 |
| AstraZeneca | 21 | $418 |
| Novartis | 16 | $301 |
| Boehringer Ingelheim | 10 | $185 |
| Bayer | 9 | $182 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $175 |
| Merck | 9 | $157 |
| Amgen(2 entities) | 5 | $94 |
| Amarin Pharma, Inc. | 4 | $87 |
| Kowa Pharmaceuticals America, Inc. | 4 | $82 |
| Pfizer | 3 | $61 |
| Johnson & Johnson | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Exact Sciences | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Mylan Specialty L.p. | 1 | $20 |
| Abbott | 1 | $17 |
| Tris Pharma Inc | 1 | $13 |
How this compares
$4,846 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 275 | $300,849 |
| OzempicSemaglutide | 206 | $238,202 |
| Tresiba Flextouch U-200Insulin Degludec | 91 | $88,073 |
| EliquisApixaban | 80 | $75,113 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $57,361 |
| FarxigaDapagliflozin Propanediol | 50 | $50,854 |
| TrulicityDulaglutide | 34 | $50,623 |
| EntrestoSacubitril/Valsartan | 37 | $41,013 |
| JardianceEmpagliflozin | 56 | $36,082 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $34,469 |
| RybelsusSemaglutide | 21 | $32,390 |
| MyrbetriqMirabegron | 42 | $30,941 |
| JanuviaSitagliptin Phosphate | 35 | $30,869 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $27,627 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $26,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $712 | $351,472309 claims |
| Novo NordiskOzempic, Rybelsus | $889 | $270,592227 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $418 | $111,655151 claims |
| PfizerEliquis | $61 | $75,11380 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Stiolto Respimat | $185 | $70,29396 claims |
| MerckJanuvia, Lagevrio (Eua), Belsomra | $157 | $44,44657 claims |
| NovartisEntresto | $301 | $41,01337 claims |
| Astellas Pharma US IncMyrbetriq | $515 | $30,94142 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $725 | $25,06520 claims |
| Johnson & JohnsonXarelto | $60 | $22,39734 claims |
| BayerKerendia | $182 | $8,69114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Sinton
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.